Drug Trial Radar · NCT00070733
The Effect of 5-Alpha Reductase on Testosterone in Men
Last checked: Nov 20, 2026Latest source record: Nov 7, 2005 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
184
Actual
Start
Aug 2003
Primary completion
Not stated
Study completion Jun 2005
Sponsor
- Lead sponsor
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)NIH
- Sponsor type
- NIH
- First posted
- Oct 10, 2003
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double
- Primary purpose
- Treatment
- Who can join
- Male only, from 21 years, up to 40 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The enzyme 5-alpha reductase is present in small amounts in muscle and converts testosterone to dihydrotestosterone (DHT). Testosterone affects lean body tissue, muscle size, muscle strength, and sexual function in men. This study will evaluate how 5-alpha reductase influences the effects of testosterone in young healthy men.
Conditions
- Sex Disorders
Interventions
testosterone enanthateDrug
duastrideDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
No primary outcomes listed.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Charles R. Drew University
Los Angeles, California · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.